Morning Glory Sciences– Author –
-
Biotech Investment News: Johnson & Johnson’s 10-Year Deal Summary & 2025 Update (2015–2025)
Strategic Review: Immunology, Oncology, and Rare Diseases at the Core of J&J’s R&D-Driven Vision Johnson & Johnson (J&J) has strategically expanded into immunology, oncology, and rare diseases by acquiring biotech compani... -
Biotech Investment News: Merck’s Major Deals from 2015 to 2025
Strategic Review: Beyond Keytruda—Pivot to Next-Gen Modalities Merck (MSD in the U.S.) built a strong oncology franchise with Keytruda. As patents expire, Merck is investing in ADCs, RNA therapies, cell therapy, and precision immunology ... -
Biotech Investment News: Pfizer’s Major Deals Over the Last Decade (2015–2025)
Strategic Review: From mRNA Success to Diversification in Rare Diseases, ADCs, and RNA Editing Pfizer strengthened its biopharmaceutical base with the acquisition of Hospira and GSK’s vaccine assets in 2015, followed by a major expansion... -
[US Research Life & Career Series #2] Three Mindsets to Prepare Before Starting Research in the U.S.
Research life in the U.S. offers diversity, dynamism, and a global environment. Surrounded by cutting-edge technologies and stimulating discussions, you’ll grow tremendously. But before jumping in, having the right mindset can make all t... -
[Science News] Long-Term Latency of Highly Mutated Cells in Esophageal Squamous Cell Carcinoma: Cancer Discovery Summary (With My Thoughts)
A study published in the June 2025 issue of Cancer Discovery reveals that highly mutated cell clones carrying multiple driver mutations can persist for many years in esophageal squamous epithelium before progressing to esophageal squamou... -
Rare & Pediatric Disease News Vol.2: How Far Can Japan Catch Up in Pediatric Rare Disease Drug Development?
– Global Comparison and Future Perspectives in the Post-PRV Era – With the expiration of the U.S. FDA’s Rare Pediatric Disease Priority Review Voucher (PRV) program in 2024, a global debate has emerged about how to sustain innovation in ... -
Oncology Drug Approval News Flash: Datopotamab deruxtecan (Datroway) Receives Accelerated FDA Approval for EGFR-mutated NSCLC
[FDA Accelerated Approval] Datroway by Daiichi Sankyo approved for EGFR-mutated non-small cell lung cancer (June 23, 2025) On June 23, 2025, the U.S. FDA granted accelerated approval to Datopotamab deruxtecan-dlnk (Datroway) for adults w... -
[In vivo CAR T Special #1] Engineering CAR T Cells Directly Inside the Body: Challenges and Opportunities
CAR T-cell therapy has revolutionized blood cancer treatment but traditionally relies on an ex vivo process—extracting T cells from patients, genetically modifying them outside the body, expanding them, and reinfusing them. This manufact... -
[Aging & Rejuvenation Science Series #1] The Hayflick Limit and Cellular Aging: Revisiting the Roots of Rejuvenation Research
Can human cells divide forever? In 1961, Leonard Hayflick and Paul Moorhead provided a clear answer to this question. Their seminal paper demonstrated that normal human diploid cells have a limited number of divisions, introducing the co... -
Oncology Drug Approval News Flash: Tisotumab vedotin-tftv (Tivdak) Approved by FDA for Recurrent or Metastatic Cervical Cancer
[FDA Approval Alert] Tisotumab vedotin-tftv by Seagen and Genmab approved for recurrent/metastatic cervical cancer (June 21, 2025) On June 21, 2025, the U.S. FDA approved Tisotumab vedotin-tftv (Tivdak) for the treatment of recurrent or ... -
[DDN Review] Antibody Combination Approach to Target Allergies at the Source: Drug Discovery News Summary (With My Thoughts)
A U.S. research team is developing a novel combination therapy of antibody drugs that directly targets the underlying causes of allergic diseases. The strategy simultaneously blocks immunoglobulin E (IgE), a key driver of allergic reacti... -
[Pharma & Biotech News] Personalized mRNA Cancer Vaccine Development Accelerates: Nature Biotechnology Review
A comprehensive review published in the June 2025 issue of Nature Biotechnology summarizes the current status of personalized mRNA cancer vaccine development. Neoantigen-based mRNA vaccines, tailored to individual patients' tumor mutatio... -
[Science News] Cell Leading Edge: Reversible Transcriptome Remodeling Controls Cellular Quiescence Entry and Exit
A study published in the June 2025 issue of Cell reveals how dynamic transcriptome remodeling orchestrates both entry into and exit from cellular quiescence. This article was selected for the journal's prominent Leading Edge feature, hig... -
Rare & Pediatric Disease News Vol.1
🧒 Introduction: Why Focus on Pediatric Rare Diseases? Pediatric rare diseases often involve life-threatening conditions with few treatment options. In 2012, the U.S. introduced the Rare Pediatric Disease Priority Review Voucher (PRV) pro... -
[RWD & Genomics Business Special] 23andMe’s Acquisition Highlights the Challenges and Opportunities in Real-World Data
23andMe, once one of the largest direct-to-consumer (DTC) genomics companies with a vast database of genetic, familial, and self-reported health data, has entered bankruptcy proceedings. While Regeneron was initially seen as a potential ... -
[AI Drug Discovery: Reality #1] How Far Has AI Drug Discovery Progressed? Sorting Hype from Reality
With the rapid evolution of artificial intelligence (AI), the concept of AI Drug Discovery has gained significant attention. Headlines often suggest that AI can now "create new drugs" or "automate drug development," raising expectations ... -
[Science News] Nature Highlight: Small Molecules Restore Mutant Mitochondrial DNA Polymerase Activity
A new study published in the June 12, 2025 issue of Nature reports that the small molecule PZL-A can directly restore the function of DNA polymerase gamma (POLγ), impaired by POLG mutations causing severe mitochondrial disorders. This wo... -
[US Research Experience and Career Pathways Series #1] 3 Things to Know Before Starting Research in the US
Starting research in a US laboratory marks an exciting new chapter of growth and challenge for many young researchers. However, the culture, values, and daily research practices in the US can differ considerably from what students may be... -
[Science News] Nuclear Pore Complex Dysfunction Underlies ALS/FTD via C9orf72 Mutations: Nature Summary (With My Thoughts)
A U.S. research team has revealed that repeat expansions in the C9orf72 gene — a major cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) — induce dysfunction of the nuclear pore complex (NPC) in neurons. In C... -
CAR T Cell Success in Solid GI Tumors: Drug Discovery News Spotlight
While CAR T cell therapies have shown success primarily in hematologic malignancies, new advances are emerging for gastrointestinal (GI) solid tumors such as colorectal, gastric, and esophageal cancers. U.S. research teams have reported ...
